- Home
- DLTH vs SPRO Comparison
DLTH vs SPRO Comparison
Compare DLTH & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLTH
- SPRO
- Stock Information
- Founded
- DLTH 1989
- SPRO 2013
- Country
- DLTH United States
- SPRO United States
- Employees
- DLTH N/A
- SPRO N/A
- Industry
- DLTH Clothing/Shoe/Accessory Stores
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- DLTH Consumer Discretionary
- SPRO Health Care
- Exchange
- DLTH Nasdaq
- SPRO Nasdaq
- Market Cap
- DLTH 131.7M
- SPRO 128.3M
- IPO Year
- DLTH 2015
- SPRO 2017
- Fundamental
- Price
- DLTH $3.45
- SPRO $2.28
- Analyst Decision
- DLTH Buy
- SPRO Buy
- Analyst Count
- DLTH 1
- SPRO 4
- Target Price
- DLTH $7.00
- SPRO $5.00
- AVG Volume (30 Days)
- DLTH 130.0K
- SPRO 381.4K
- Earning Date
- DLTH 09-04-2025
- SPRO 11-13-2025
- Dividend Yield
- DLTH N/A
- SPRO N/A
- EPS Growth
- DLTH N/A
- SPRO N/A
- EPS
- DLTH N/A
- SPRO N/A
- Revenue
- DLTH $602,746,000.00
- SPRO $48,576,000.00
- Revenue This Year
- DLTH N/A
- SPRO N/A
- Revenue Next Year
- DLTH $0.24
- SPRO N/A
- P/E Ratio
- DLTH N/A
- SPRO N/A
- Revenue Growth
- DLTH N/A
- SPRO N/A
- 52 Week Low
- DLTH $1.58
- SPRO $0.51
- 52 Week High
- DLTH $4.66
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- DLTH 50.66
- SPRO 61.62
- Support Level
- DLTH $3.22
- SPRO $1.84
- Resistance Level
- DLTH $3.94
- SPRO $2.42
- Average True Range (ATR)
- DLTH 0.27
- SPRO 0.10
- MACD
- DLTH -0.10
- SPRO 0.04
- Stochastic Oscillator
- DLTH 23.91
- SPRO 71.55
About DLTH Duluth Holdings Inc. Class B
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.